Joseph Crivelli

Dr. Joseph Crivelli

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JCJoseph Crivelli
Joseph Crivelli
TMTanecia Mitchell
Tanecia Mitchell
JKJohn Knight
John Knight
KWKyle D. Wood
Kyle D. Wood
DADean G. Assimos
Dean G. Assimos
SFSonia Fargue
Sonia Fargue
Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate intake and endogenous production of oxalate are important in the pathophysiology of calcium oxalate stone disease. The impact of dietary oxalate intake on urinary oxalate excretion and kidney stone disease risk has been assessed through large cohort studies as well as smaller studies with dietary control. Net gastrointestinal oxalate absorption influences urinary oxalate excretion. Oxalate-degrading bacteria in the gut microbiome, especially Oxalobacter formigenes, may mitigate stone risk through reducing net oxalate absorption. Ascorbic acid (vitamin C) is the main dietary precursor for endogenous production of oxalate with several other compounds playing a lesser role. Renal handling of oxalate and, potentially, renal synthesis of oxalate may contribute to stone formation. In this review, we discuss dietary oxalate and precursors of oxalate, their pertinent physiology in humans, and what is known about their role in kidney stone disease.

27 April 2021 in Journal of Urology
Verified
Journal Article
Closed access
JCJoseph Crivelli
Joseph Crivelli
NMNaim M. Maalouf
Naim M. Maalouf
HPHenry J. Paiste
Henry J. Paiste
KWKyle D. Wood
Kyle D. Wood
AHAmy E. Hughes
Amy E. Hughes
DADean G. Assimos
Dean G. Assimos
Purpose:To review the available evidence regarding health disparities in kidney stone disease and identify knowledge gaps in this area.Materials and Methods:A literature search was conducted using ...

1 December 2021 in International braz j urol
Verified
Journal Article
Open access
JCJoseph Crivelli
Joseph Crivelli
BJBrett A. Johnson
Brett A. Johnson
RSRyan L. Steinberg
Ryan L. Steinberg
JGJeffrey C. Gahan
Jeffrey C. Gahan
JAJodi A. Antonelli
Jodi A. Antonelli
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu
Purpose: We aimed to assess failure rates of salvage interventions and changes in split kidney function (SKF) following failed primary repair of ureteropelvic junction obstruction (UPJO). Materials and methods: A retrospective review of adult patients at an academic medical center who underwent salvage intervention following primary treatment for UPJO was performed. Symptomatic failure was defined as significant flank pain. Radiographic failure was defined as no improvement in drainage or a decrease in SKF by >= 7%. Overall failure, the primary outcome, was defined as symptomatic failure, radiographic failure, or both. Results: Between 2008-2017, 34 patients (median age 38 years, 50% men) met study criteria. UPJO management was primary pyeloplasty/secondary endopyelotomy for 21/34 (62%), primary pyeloplasty/secondary pyeloplasty for 6/34 (18%), and primary endopyelotomy/secondary pyeloplasty for 7/34 (21%). Median follow-up was 3.3 years following secondary intervention. Patients undergoing primary pyeloplasty/secondary endopyelotomy had significantly higher overall failure than those undergoing primary pyeloplasty/secondary pyeloplasty (16/21 [76%] vs. 1/6 [17%], p=0.015). Among patients undergoing secondary endopyelotomy, presence of a stricture on retrograde pyelogram, stricture length, and SKF were not associated with symptomatic, radiographic, or overall failure. Serial renography was performed for 28/34 (82%) patients and 2/28 (7%) had a significant decline in SKF. Conclusions: Following failed primary pyeloplasty, secondary endopyelotomy had a greater overall failure rate than secondary pyeloplasty. No radiographic features assessed were associated with secondary endopyelotomy failure. Secondary intervention overall failure rates were higher than reported in the literature. Unique to this study, serial renography demonstrated that significant functional loss was overall infrequent.

17 June 2022 in American Journal of Preventive Medicine
Verified
Journal Article
Open access
JCJoseph Crivelli
Joseph Crivelli
DRDavid T. Redden
David T. Redden
RJRobert D. Johnson
Robert D. Johnson
LJLucia D Juarez
Lucia D Juarez
NMNaim M. Maalouf
Naim M. Maalouf
GOGabriela R. Oates
Gabriela R. Oates
Obesity is associated with kidney stone disease (KSD), but it is unknown whether this association differs by SES. This study assessed the extent to which obesity and neighborhood characteristics jointly contribute to urinary risk factors for KSD. This was a retrospective analysis of adult patients with KSD evaluated with 24-hour urine collection (2001-2020). Neighborhood-level socioeconomic data were obtained for a principal component analysis (PCA), which identified 3 linearly independent factors. Associations between these factors and 24-hour urine measurements were assessed using linear regression, as well as groupings of 24-hour urine results using multivariable logistic regression. Finally, multiplicative interactions were assessed testing effect modification by obesity, and analyses stratified by obesity were performed. Analyses were performed in 2021. In total, 1,264 patients met study criteria. Factors retained on PCA represented SES, family structure, and housing characteristics. On linear regression, there was a significant inverse correlation between SES and 24-hour urine sodium (p=0.0002). On multivariable logistic regression, obesity was associated with increased odds of multiple stone risk factors (OR: 1.61; 95% CI: 1.15-2.26) and multiple dietary factors (OR: 1.33; 95% CI: 1.06-1.67). No significant and consistent multiplicative interactions were observed between obesity and quartiles of neighborhood SES, family structure, or housing characteristics. Obesity was associated with the presence of multiple stone risk factors and multiple dietary factors; however, the strength and magnitude of these associations did not vary significantly by neighborhood SES, family structure, and housing characteristics.

1 July 2023 in Urology Practice
Verified
Journal Article
Closed access
JCJoseph Crivelli
Joseph Crivelli
PYPhyllis L. Yan
Phyllis L. Yan
VSVahakn Shahinian
Vahakn Shahinian
RHRyan S. Hsi
Ryan S. Hsi
JHJohn M. Hollingsworth
John M. Hollingsworth
The AUA Medical Management of Kidney Stones guideline outlines recommendations on follow-up testing for patients prescribed preventive pharmacological therapy. We evaluated adherence to these recommendations by provider specialty. Using claims data from working-age adults with urinary stone disease (2008-2019), we identified patients prescribed a preventive pharmacological therapy agent (a thiazide diuretic, alkali citrate therapy, allopurinol, or a combination thereof) and the specialty of the prescribing physician (urology, nephrology, and general practice). Next, we identified patients who completed a 24-hour urine collection prior to their prescription fill. We then measured adherence to 3 recommendations outlined in the AUA guideline. Finally, we fit multivariable logistic regression models evaluating associations between prescribing provider specialty and adherence to recommended follow-up testing. Among 2,600 patients meeting study criteria, 1,523 (59%) adhered to ≥1 follow-up testing recommendation, with a significant increase over the study period. Nephrologists had higher odds of adherence to ≥1 follow-up test compared to urologists (odds ratio, 1.52; 95% confidence interval, 1.19-1.94; P < .01). Significant differences in adherence to the 3 individual guideline recommendations were also observed by specialty. Following initiation of preventive pharmacological therapy, adherence to guideline-recommended follow-up testing was low overall. There exist meaningful specialty-specific differences in the use of this testing.

1 December 2024 in JU Open Plus
Verified
Journal Article
Open access
KSKevin B. Smith
Kevin B. Smith
JCJoseph Crivelli
Joseph Crivelli
PYPhyllis L. Yan
Phyllis L. Yan
RHRyan S. Hsi
Ryan S. Hsi
VSVahakn B. Shahinian
Vahakn B. Shahinian
BDBrian T. Denton
Brian T. Denton
Purpose: Preventive pharmacological therapy (PPT) is recommended for certain patients with urinary stone disease to reduce their recurrence risk, but they frequently do not adhere. With causal inference methods, we evaluated whether follow-up urine testing could be used to improve PPT adherence. Materials and Methods: Using claims data from Optum’s deidentified Clinformatics Data Mart database (2008-2019), we identified patients with urinary stone disease who were prescribed PPT (thiazide diuretic, alkali therapy, or allopurinol) after baseline 24-hour urine testing and assessed their adherence with the proportion of days covered method. After distinguishing between patients who did and did not receive follow-up urine testing, we examined the association between follow-up testing and PPT adherence with logistic regression. We then emulated a target trial using propensity score matching, stratification, and doubly robust estimators to estimate the equivalent causal effect. Results: Among 4166 patients, 496 (11.9%) completed both baseline and follow-up testing. Follow-up testing was associated with a 9.0% increase in adherence odds after adjusting for sociodemographic, behavioral, and disease-related and treatment-related patient characteristics. Furthermore, we estimated a 7.1% increase in proportion of days covered caused by follow-up testing using causal inference methods. Subgroup analyses indicated the most significant effects are among women, those with low baseline medication adherence, and those not at high risk of stone formation. Conclusions: These data suggest that follow-up urine testing after starting PPT may have a beneficial effect on long-term medication adherence.